• FirefoxInstall the new Firefox »
  •  Dow Up0.21% Nasdaq Up0.32%

    PTC Therapeutics, Inc. (PTCT)

    72.72 Up 2.26(3.21%) Mar 5, 3:59PM EST
    Add to Portfolio
    ProfileGet Profile for:
    PTC Therapeutics, Inc.
    100 Corporate Court
    South Plainfield, NJ 07080
    United States - Map
    Phone: 908-222-7000
    Fax: 908-222-7231
    Website: http://www.ptcbio.com

    Index Membership:N/A
    Full Time Employees:187

    Business Summary 

    PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and PTC672, an antibacterial development candidate for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program. The company was founded in 1998 and is based in South Plainfield, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on PTC Therapeutics, Inc.

    Corporate Governance 
    PTC Therapeutics, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Stuart W. Peltz Ph.D., 55
    Co-Founder, Chief Exec. Officer and Exec. Director
    Dr. Allan Steven Jacobson Ph.D., 69
    Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating and Corp. Governance Committee
    Mr. Mark A. Rothera , 52
    Chief Commercial Officer
    Mr. Shane William Charles Kovacs , 41
    Chief Financial Officer, Principal Accounting Officer, Head of Corp. Devel. and Exec. VP
    Jane Baj ,
    Associate Director of Public & Investor Relations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders